RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018.

Fludeoxyglucose (18F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

RTM receives marketing authorisation for Fludeoxyglucose (18F)

Other news

First liver cancer patient treated with microspheres irradiated in TU Delft

First liver cancer patient treated with microspheres irradiated in TU Delft

Radboud Translational Medicine will perform the dispensing of below product. The production and dis...

Read more

18F-FDOPA now available

18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...

Read more

Upcoming event

Upcoming event

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...

Read more

1st production QuiremSpheres

1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the s...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.